Biotechnology // Browsing posts in Biotechnology
Aurinia Pharmaceuticals Idea Proposal (AUPH)
Will Aurinia’s launch of Lupkynis withstand the challenges of COVID, competition, and the existing standard-of-care to attain significant sales success? Report Available: July 29, 2021 Blueshift’s initial research found AUPH in the early launch stage of its new drug, Lupkynis for the treatment of lupus nephritis (LN). Lupkynis’ approval came on the heels of […]
Medtronic Losing; Dexcom, Abbott, Insulet Winning in the Diabetes Market (MDT, DXCM, ABT, PODD)
Research Question: Are any of the diabetes wearables market’s key players setting themselves apart and gaining significant share? Companies: ABT, DXCM, MDT, MNKD, PODD, SENS, TNDM By: David Franklin Click here to download report (.pdf) Summary of Findings The diabetes wearable market is growing and its key device providers are secure in their […]
Cardiovascular Systems Idea Proposal (CSII)
Will Cardiovascular Systems extend its growth trend, or will it be disrupted by ShockWave and other competitors? Report Available: March 10, 2021 Blueshift’s initial research found the coronary artery disease (CAD) and peripheral artery disease (PAD) treatment space poised for solid recovery as the coronavirus pandemic medical procedure moratorium begins to subside. Two device […]
Neuronetics Faces Significant Headwinds to Reinvigorate Growth (STIM)
Research Question: Will Neuronetics’ C-suite changes, new treatment indication, expanded reimbursement, and new positive data reinvigorate growth? Companies: BWAY, GTMS, NXTMH.HE, STIM By: David Franklin Click here to download report (.pdf) Summary of Findings Neuronetics Inc.‘s (STIM) business model, requiring psychiatric practices and TMS (transcranial magnetic stimulation) clinics to spend significant sums to acquire […]
Neuronetics Idea Proposal (STIM)
Will Neuronetics’ C-suite changes, new treatment indication, expanded reimbursement, and new positive data reinvigorate growth? Report Available: November 4, 2020 Blueshift’s initial research found STIM, a leader in providing transcranial magnetic stimulation (TMS) therapy equipment and support for the treatment of Major Depressive Disorder (MDD), navigating through the coronavirus, which has had a significant […]
Slow and Steady Recovery Likely for Axogen (AXGN)
Research Question: Is the stronger-than-expected second-quarter demand Axogen experienced for its nerve regeneration products sustainable? Companies: ABBV, AXGN, HSIC, IART, SYK By: David Franklin Click here to download report (.pdf) Summary of Findings Sources were mixed trending positive regarding Axogen Inc.’s (AXGN) ability to sustain the stronger-than-expected Q2 demand for its nerve repair and […]
Axogen Idea Proposal (AXGN)
Is the stronger-than-expected Q2 demand Axogen experienced for its nerve regeneration products sustainable? Report Available: October 8, 2020 Blueshift’s initial research found AXGN, the leader in the development and commercialization of technologies for peripheral nerve regeneration and repair, experiencing a strong rebound in growth following the late Q1 and early Q2 2020 sales declines […]
Insulin Pump Market Idea Proposal (TNDM, PODD, MDT)
As the continuous glucose monitoring market continues to innovate, integrate, and grow, are insulin pump makers Tandem, Insulet, and Medtronic poised to follow? Report Available: September 3, 2020 Blueshift’s initial research found the continues glucose monitoring (CGM) market experiencing increasing demand from both Type 1 and Type 2 diabetics. The CGM space has also […]
Chembio Will Benefit from High COVID-19 Antibody Testing Demand (CEMI)
Research Question: Will Chembio’s DPP COVID-19 system gain and sustain commercial success? How will sensitivity and specificity concerns impact adoption of COVID-19 point-of-care tests? Companies: ABT, BIM.PA, CEMI, DGX, LH, RHHBY, TMO, 688298:SHA By: David Franklin Click here to download report (.pdf) Summary of Findings Chembio Diagnostics Inc.’s (CEMI) Dual Path Platform (DPP) COVID-19 […]
Chembio Diagnostics Idea Proposal (CEMI)
How will sensitivity and specificity concerns impact adoption of COVID-19 point-of-care tests? Will Chembio’s DPP COVID-19 System gain and sustain commercial success? Report Available: June 11, 2020 Blueshift’s initial research found the medical/pharma industrial complex engaging in a massive COVID-19 related effort to produce personal protective equipment, coronavirus testing systems and treatments. Over 180 […]
Copyright © 2015 Blueshift Research, LLC. All rights reserved.
